Aliment Pharmacol Ther. 2007 Jan 15;25(2):177-84.
A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children.
Gawronska A, Dziechciarz P, Horvath A, Szajewska H. Department of Paediatric Gastroenterology and Nutrition, The Medical University of Warsaw, Warsaw, Poland.
Background Functional abdominal pain disorders (FAPD) are common in school-aged children; however, there is no reliable treatment. Aim To determine the efficacy of Lactobacillus rhamnosus GG (LGG) for treating FAPD in children. Methods A total of 104 children who fulfilled the Rome II criteria for functional dyspepsia (FD), or irritable bowel syndrome (IBS), or functional abdominal pain (FAP) were enrolled in a double-blind, randomized controlled trial in which they received LGG (n = 52), or placebo (n = 52) for 4 weeks. Results For the overall study population, those in the LGG group were more likely to have treatment success (no pain) than those in the placebo group (25% vs. 9.6%, relative benefit (RB) 2.6, 95% confidence interval (CI): 1.05-6.6, number needed to treat (NNT) 7, 95% CI: 4-123). For children with IBS (n = 37), those in the LGG group were more likely to have treatment success than those in the placebo group (33% vs. 5%, RB 6.3, 95% CI: 1.2-38, NNT 4, 95% CI: 2-36) and reduced frequency of pain (P = 0.02), but not pain severity (P = 0.10). For the FD group (n = 20) and FAP group (n = 47), no differences were found. Conclusion The LGG appears to moderately increase treatment success, particularly among children with IBS.
PMID: 17229242 [PubMed - in process]